Alpha-Synuclein Prion-Like Spreading Mechanisms in Parkinson's Disease
Overview
Alpha-synuclein ([α-syn](/proteins/alpha-synuclein)) prion-like spreading represents one of the most transformative concepts in understanding Parkinson's disease ([PD](/diseases/parkinsons-disease)) pathogenesis and progression. This mechanism proposes that misfolded α-syn aggregates can propagate between neurons, templating the conversion of native monomeric proteins into pathological aggregates, thereby spreading neurodegeneration across the brain in a predictable pattern[@braak2003][@jucker2011].
The prion-like hypothesis emerged from multiple converging lines of evidence: the identification of Lewy bodies (LB) containing fibrillar α-syn in PD brains, the observation that fetal tissue grafts in PD patients developed LB-like pathology years after transplantation, and the demonstration that α-syn aggregates can be transmitted between cells in culture and in animal models[@kalia2013][@visanji2016]. This page comprehensively reviews the molecular mechanisms of α-syn aggregation, cell-to-cell transmission, templating, and the anatomical patterns of spreading that characterize PD progression.
Prion-Like Spreading Cascade
Mermaid diagram (expand to render)
Pathway summary: Genetic and environmental triggers promote alpha-synuclein misfolding, leading to oligomer formation. Toxic oligomers cause synaptic dysfunction and neuronal stress through multiple mechanisms (membrane pores, mitochondrial damage, proteostasis impairment). Stressed neurons release aggregates via exocytosis, exosomes, and tunneling nanotubes. Recipient cells internalize alpha-synuclein through endocytosis, where endosomal escape enables templating of native protein misfolding, creating a self-propagating cycle. Parallel microglial activation drives neuroinflammation that further accelerates aggregation. Mature fibrils accumulate in Lewy bodies, causing synaptic loss and dopaminergic neurodegeneration, manifesting as progressive motor and non-motor PD symptoms.
Molecular Basis of alpha-Synuclein Pathology
Structure and Aggregation Propensity
Alpha-synuclein is a 140-amino-acid protein encoded by the [SNCA](/genes/snca) gene, predominantly expressed in presynaptic terminals of neurons[@spillantini1997]. The protein comprises three distinct domains:
N-terminal domain (residues 1-60): Contains seven imperfect repeats with the KTKEGV motif, which mediate membrane binding and are sites of pathogenic mutations
NAC region (residues 61-95): The non-amyloid-β component (NAC) domain contains the hydrophobic sequence "VQVVY" and is critical for aggregation
C-terminal domain (residues 96-140): Highly acidic and proline-rich, thought to inhibit aggregation under normal conditionsThe aggregation of α-syn into fibrils proceeds through a nucleation-dependent process involving multiple intermediate species:
- Monomeric α-syn: Native unfolded protein in neuronal cytoplasm
- Oligomeric intermediates: Small aggregates (dimers, trimers, protofibrils) that may be more toxic than mature fibrils
- Fibrillar aggregates: β-sheet rich fibrils that constitute the core of Lewy bodies
- Lewy bodies: Large cytoplasmic inclusions containing fibrils, membranes, and associated proteins
The transition from monomer to fibril involves structural conversion from random coil/α-helical to β-sheet rich conformations, a process that can be accelerated by mutations ([SNCA A53T](/genes/snca), [SNCA A30P](/genes/snca), [SNCA E46K](/genes/snca), post-translational modifications (phosphorylation at Ser129), and environmental factors[@conway1998][@fujiwara2002].
Post-Translational Modifications
α-Syn undergoes numerous post-translational modifications (PTMs) that influence its aggregation propensity:
- Ser129 phosphorylation: Approximately 90% of α-syn in LBs is phosphorylated at Ser129, making it a specific pathological marker[@fujiwara2002a]
- Ubiquitination: Multi-ubiquitin chains decorate LB-associated α-syn, targeting it for proteasomal degradation[@hasegawa2002]
- Nitration: Oxidative stress leads to tyrosine nitration, promoting oligomerization[@giasson2000]
- Truncation: C-terminal truncation at residue 120/121 enhances aggregation and fibril formation[@liu2005]
Strains and Polymorphism
Recent research has revealed that α-syn aggregates can form distinct strains with different structural and biological properties, analogous to prion strains:
- Cortical-type strains: Isolated from diffuse Lewy body disease (DLBD) cases
- brainstem-type strains: Isolated from classic PD cases
- MSA-type strains: Isolated from multiple system atrophy (MSA) cases
These strains show different incubation periods, pathological distributions, and seeding capacities when inoculated into animal models, suggesting that strain diversity contributes to the clinical heterogeneity of α-synucleinopathies[@peelaerts2015][@boutajangout2011].
Cell-to-Cell Transmission Mechanisms
Secretion Pathways
Pathological α-syn can be released from neurons through multiple mechanisms:
Exocytosis: Activity-dependent release from synaptic terminals[@emmanouilidou2010]
Exosomes: Extracellular vesicles containing α-syn oligomers and fibrils[@grey2015]
Tunneling nanotubes: Membrane protrusions that allow direct cell-to-cell transfer[@wang2017]
Membrane leakage: Pore formation by toxic oligomers[@kayed2003]The secretion is influenced by neuronal activity, cellular stress, and specific mutations. For example, [SNCA A53T](/genes/snca) mutations enhance exosomal release of α-syn, potentially accelerating propagation[@sung2005].
Once outside the cell, α-syn aggregates encounter the extracellular environment where they:
- Interact with cell membranes of neighboring neurons via receptor-mediated endocytosis
- Activate microglia through Toll-like receptor 2 (TLR2) and TLR4, triggering neuroinflammation
- Bind to extracellular matrix proteins that may facilitate or inhibit diffusion
- Undergo proteolytic cleavage by extracellular proteases
Internalization Mechanisms
Recipient cells take up extracellular α-syn through several pathways:
- Receptor-mediated endocytosis: Involvement of cellular prion protein (PrP^C), LRP1, and NMDA receptors[@auluck2010]
- Direct membrane translocation: Possible for small oligomers
- Exosome-mediated delivery: Protected from degradation within extracellular vesicles
- Phagocytosis: Microglial uptake of extracellular aggregates
Following internalization, α-syn can escape endosomes into the cytoplasm through pH-dependent mechanisms or endosomal membrane disruption, allowing it to template the conversion of endogenous α-syn[@desplats2009].
Templating and Seeding Mechanisms
Nucleation and Cross-Seeding
The prion-like nature of α-syn is defined by its ability to template the misfolding of native proteins:
Primary nucleation: Spontaneous formation of aggregates from monomers (rare)
Secondary nucleation: Aggregation catalyzed by existing aggregate surfaces (faster)
Autocatalytic growth: Continuous addition of monomers to fibril ends
Fragmentation: Mechanical or enzymatic cleavage of fibrils creating new seedsα-syn fibrils can cross-seed with other amyloidogenic proteins (Aβ, tau) under certain conditions, potentially explaining the co-occurrence of multiple proteinopathies in some cases[@guo2013].
Template-Directed Misfolding
The template-directed misfolding involves:
- Surface-catalyzed conversion: Exposed β-sheets on fibril surfaces template the conversion of incoming monomers
- Strain-specific templating: Each fibril strain imposes its conformation on newly recruited monomers
- Strain interference: Co-assembly of different strains can attenuate or enhance pathology
The efficiency of seeding varies with the conformation of the seed, with brain-derived α-syn generally being more efficient at seeding than recombinant fibrils[@luk2016].
Anatomical Patterns of Spreading
Braak Staging and Lewy Body Progression
The pattern of alpha-syn pathology in sporadic PD follows the Braak staging scheme:
Mermaid diagram (expand to render)
This ascending progression from lower brainstem to cortical regions is hypothesized to reflect either:
Anatomical spread via neural connections (prion-like propagation)
Independent vulnerability of neuronal populations (not necessarily spreading)Propagation Along Neural Networks
Evidence supports trans-synaptic spread along connected circuits:
- Olfactory pathway: Early olfactory involvement correlates with olfactory bulb pathology
- Autonomic nerves: Cardiac sympathetic denervation precedes motor symptoms
- Subcortical circuits: Progression through basal ganglia-thalamocortical loops
- Cortico-cortical networks: Late-stage cortical spread
Network-based models predict that regions with high connectivity to early-affected areas show earlier pathology, consistent with a spreading mechanism[@zhang2016].
Animal Models of α-Syn Spreading
Rodent Models
Multiple models demonstrate cell-to-cell transmission:
- Injections of preformed fibrils: Inoculation into striatum or cortex leads to widespread α-syn pathology that spreads to connected regions[@luk2012]
- Overexpression models: Viral vector-mediated [SNCA](/genes/snca) overexpression causes progressive pathology
- Transgenic models: M83, M47, Line 61 mice develop age-dependent α-syn pathology
Non-Human Primate Models
Primate models show more faithful recapitulation of human pathology:
- Rhesus macaques injected with α-syn fibrils develop Lewy body-like inclusions
- Progressive motor and non-motor phenotypes emerge
- Trans-synaptic spread can be demonstrated using retrograde tracers
Clinical Implications
Biomarker Development
α-Syn spreading mechanisms have enabled new biomarker strategies:
- Seed amplification assays: RT-QuIC and PMCA detect pathological α-syn in CSF, skin, olfactory mucosa
- Exosomal α-syn: Plasma exosome α-syn as a biomarker for prodromal PD
- Imaging agents: PET ligands for α-syn aggregates in development
Therapeutic Strategies
Understanding spreading mechanisms has opened new therapeutic avenues:
Aggregation inhibitors: Small molecules preventing fibril formation (Anle138b, CLR01)
Antibody therapies: Passive immunization targeting extracellular α-syn (cinpanemab, prasinezumab)
Active vaccination: PD03A vaccine targeting phosphorylated Ser129 α-syn
Gene silencing: ASO and siRNA approaches targeting [SNCA](/genes/snca) expression
Propagation blockers: Compounds interfering with cell-to-cell transmissionRisk Factors and Modifiers
Genetic Modifiers
Genetic variants affecting spreading:
- [SNCA](/genes/snca): Multiplication, point mutations enhance propagation
- [LRRK2](/genes/lrrk2): Mutations may affect exosome function
- [GBA](/genes/gba): Carrier status accelerates progression
- [COMT](/genes/comt): Polymorphism affects dopamine metabolism and possibly α-syn dynamics
Environmental Factors
Environmental contributors to spreading:
- Traumatic brain injury enhances susceptibility to post-traumatic neurodegeneration
- Mitochondrial toxins (MPTP, rotenone) can accelerate α-syn pathology
- Metal exposure (iron, copper) promotes aggregation
- Sleep disruption may increase extracellular α-syn
Cellular and Circuit-Level Mechanisms
Synaptic Dysfunction and Neuronal Vulnerability
α-Syn pathology exerts profound effects on synaptic function prior to visible aggregate formation. The earliest detectable changes in PD involve synaptic dysfunction rather than overt neurodegeneration, with multiple mechanisms contributing to this impairment.
Presynaptic alterations:
- Impaired synaptic vesicle recycling and replenishment, leading to depletion of readily releasable pool
- Reduced dopamine release from surviving terminals despite relatively preserved neuronal counts
- Alterations in synaptic vesicle protein composition, including synaptophysin and synaptotagmin changes
- Disruption of synapsin phosphorylation and vesicle clustering at terminal sites
- Elevated basal cytosolic calcium in terminals promoting neurotransmitter depletion
Postsynaptic impacts:
- Altered NMDA and AMPA receptor trafficking, affecting synaptic plasticity
- Impaired long-term potentiation (LTP) in hippocampal neurons, correlating with cognitive deficits
- Dendritic spine loss in affected regions, particularly in striatal medium spiny neurons
- Dysregulation of postsynaptic density proteins including PSD-95 and Homer
- Abnormalities in GABAergic and cholinergic signaling in downstream circuits
The selective vulnerability of dopaminergic neurons in [substantia nigra pars compacta](/brain-regions/substantia-nigra) relates to their unique physiological properties. These neurons exhibit:
- High basal oxidative phosphorylation rates due to autonomous pacemaking activity
- Substantial mitochondrial stress from continuous ATP demands
- Large synaptic terminal fields requiring sustained vesicle cycling
- Intracellular calcium oscillations driven by L-type channels that promote oxidative stress
- High iron content that can catalyze reactive oxygen species generation
These factors create a "perfect storm" promoting α-syn aggregation and propagation in dopaminergic neurons. The high firing rates, enormous axonal arbors (each neuron innervates approximately 500,000 striatal neurons), and metabolic demands make these cells particularly susceptible to proteostatic failure and subsequent propagation[@cheng2010][@lundblad2012].
Glial Interactions and Neuroinflammation
The spreading of α-syn pathology triggers robust glial responses that significantly influence disease progression. Neuroinflammation is not merely a secondary phenomenon but actively contributes to pathology propagation through multiple mechanisms.
Microglial activation:
Pattern recognition receptors on microglia recognize extracellular α-syn aggregates:
- Toll-like receptor 2 (TLR2) and TLR4 activation by aggregated α-syn
- CD14-mediated recognition of exosomal α-syn
- NLRP3 inflammasome activation leading to IL-1β maturation
- NF-κB activation and pro-inflammatory cytokine release (TNF-α, IL-6, IL-1β)
- Chronic activation leading to progressive neurodegeneration through sustained oxidative stress
Microglia may play a dual role in propagation—potentially clearing pathological aggregates while simultaneously amplifying toxicity through cytokine release. The balance between these functions may determine disease progression rate.
Astrocytic responses:
Astrocytes surrounding Lewy bodies exhibit characteristic changes:
- Reactive gliosis with upregulated GFAP expression
- Impaired astrocytic glutamate uptake potentially contributing to excitotoxicity
- Altered potassium buffering affecting neuronal excitability
- Potential contribution to protein clearance through lysosomal pathways
- Secretion of inflammatory mediators that recruit additional immune cells
The neuroinflammatory response creates a feed-forward loop where:
Extracellular α-syn activates microglia via TLR signaling
Inflammatory cytokines (especially TNF-α and IL-1β) promote further α-syn aggregation
Affected neurons release more α-syn through compromised membrane integrity
Pathology spreads to connected cells in neural networks[@harrison2020]While Lewy bodies represent the pathological hallmark of PD, growing evidence suggests that soluble oligomeric intermediates may be the primary toxic species driving neurodegeneration. The "oligomer hypothesis" proposes that prefibrillar aggregates are more pathogenic than mature fibrils.
Oligomer characteristics:
- Diameter range of 2-100 nm depending on aggregation state
- Prefibrillar conformation with exposed β-sheet rich surfaces
- Membrane-permeabilizing capability through pore-like structures
- Synaptic dysfunction at picomolar concentrations in vitro
- Capability to spread between cells more efficiently than fibrils
Mechanisms of oligomer toxicity:The toxic effects of oligomers operate through several interconnected pathways:
- Membrane pore formation: Oligomeric α-syn can insert into lipid bilayers, creating cation-selective channels that disrupt ionic homeostasis and trigger calcium dysregulation
- Mitochondrial dysfunction: Oligomers bind to mitochondrial proteins, impairing electron transport chain Complex I activity and promoting ROS generation
- Proteostasis impairment: Oligomers inhibit the proteasome and autophagy machinery, compromising the cell's ability to clear misfolded proteins
- Synaptic vesicle depletion: Direct interaction with synaptic vesicles disrupts neurotransmitter packaging and release
- ER stress activation: Oligomer accumulation in the endoplasmic reticulum triggers the unfolded protein response and promotes apoptosis
The balance between oligomer formation, fibrilization, and clearance determines the progression of pathology. Fibrils may represent a relatively inert "sink" for toxic oligomers, explaining why some individuals with extensive LB pathology show relatively preserved neuronal function—a phenomenon termed "resilience"[@cremades2012][@rockenstein2014].
Propagation Along Specific Neural Pathways
Dorsal Vagal Route
The earliest and most consistent pathology in PD involves the dorsal motor nucleus of the vagus nerve (DMNV), suggesting that the disease may initiate in the peripheral nervous system and propagate centripetally to the brain.
Anatomical basis:
- Parasympathetic preganglionic neurons in the DMNV project to peripheral organs via the vagus nerve
- The vagus provides extensive innervation to the gastrointestinal tract, heart, and lungs
- These neurons have long, thinly myelinated axons susceptible to various insults
Centrifugal spread hypothesis:
- Pathology may begin in the gastrointestinal tract and propagate retrogradely
- Evidence from biopsies shows α-syn in enteric nervous system (ENS) years before brain involvement
- The presence of Lewy bodies in the vagus nerve of early PD patients supports this route
Clinical correlates:
- Gastrointestinal symptoms (constipation, nausea, early satiety) often precede motor signs by years
- Constipation can occur up to 20 years before diagnosis
- The timing of GI symptoms correlates with predicted disease onset based on Braak staging
This "body-first" progression model suggests that pathology may initiate in the peripheral nervous system and propagate centripetally via the vagus nerve to the brainstem, consistent with Braak stages 1-2. The identification of α-syn in the ENS of patients with idiopathic REM sleep behavior disorder (a prodromal PD marker) further supports this hypothesis[@braak2003a].
Mesolimbic and Mesocortical Pathways
The dopaminergic mesocorticolimbic system shows early involvement in PD, explaining the non-motor symptoms that often precede motor manifestations.
Ventral tegmental area (VTA) projections:
- Nucleus accumbens: Reward processing deficits leading to anhedonia and depression
- Prefrontal cortex: Executive dysfunction including planning, working memory, and cognitive flexibility
- Amygdala: Mood and emotional processing alterations contributing to anxiety and apathy
- Hippocampus: Memory formation and consolidation impairments
The progressive involvement of these pathways explains the sequence of non-motor symptoms in PD:
- Hyposmia (loss of smell) often first, correlating with olfactory bulb involvement
- Autonomic dysfunction (orthostatic hypotension, urinary symptoms) reflecting peripheral and central autonomic system involvement
- Sleep disorders including REM sleep behavior disorder
- Mood disorders (depression, anxiety) appearing before motor symptoms
- Cognitive impairment emerging later in disease course
Basal Ganglia Circuitry
The motor symptoms of PD arise from progressive disruption of basal ganglia circuits controlling movement. Understanding this circuitry is essential for interpreting how α-syn propagation leads to the classic parkinsonian triad of tremor, bradykinesia, and rigidity.
Direct and indirect pathway disruption:
- Progressive loss of dopaminergic neurons in substantia nigra pars compacta
- Abnormal β-band oscillations (13-30 Hz) in the subthalamic nucleus and globus pallidus
- Aberrant firing patterns propagating through motor thalamus and cortical areas
- Imbalance between direct (facilitates movement) and indirect (inhibits movement) pathways
Pathology spread through circuits:
- Posterior striatum (putamen) shows earliest α-syn pathology
- Progressive involvement of external globus pallidus (GPe) and subthalamic nucleus
- Thalamic relay disruption contributing to akinesia
- Motor cortex involvement in advanced disease explaining gait freezing and postural instability
Comparative Analysis with Other Neurodegenerative Diseases
Parkinson's Disease vs. Multiple System Atrophy
While both PD and multiple system atrophy (MSA) are classified as α-synucleinopathies, they show distinct pathological and clinical features that illuminate fundamental differences in propagation mechanisms.
| Feature | Parkinson's Disease | Multiple System Atrophy |
|---------|---------------------|------------------------|
| Primary α-syn inclusion type | Lewy bodies | Glial cytoplasmic inclusions (GCIs) |
| Predominant strain | brainstem-type | MSA-type |
| Propagation pattern | Network-based, predictable | Diffuse, widespread |
| Clinical progression | Gradual over years | Rapid over 5-7 years |
| Treatment response | L-DOPA responsive initially | Poor, minimal benefit |
| Regional vulnerability | Substantia nigra, brainstem | Oligodendrocytes, brainstem |
The strain differences explain the distinct clinical phenotypes and pathological distributions. MSA-derived α-syn fibrils show different structural properties and when introduced into animal models, produce pathology predominantly in oligodendrocytes rather than neurons—a pattern consistent with human MSA[@fairfoul2016].
Lewy Body Dementia
Diffuse Lewy body disease (DLBD), also termed dementia with Lewy bodies (DLB), represents another α-synucleinopathy with distinct characteristics from PD:
- More extensive cortical involvement than PD, explaining the prominent cognitive symptoms
- Prominent cholinergic deficits from nucleus basalis involvement, contributing to attention deficits
- Visual hallucinations as early feature, often preceding motor symptoms
- Fluctuating cognition with pronounced variations in alertness and attention
- Faster progression than PD, with median survival of 5-7 years from diagnosis
- Different α-syn strain characteristics, with cortical-type strains predominating
The relationship between PD and DLB remains debated—are they distinct diseases or opposite ends of a spectrum? The answer likely depends on the specific α-syn strain involved and host factors influencing propagation[@valera2017].
Future Directions
Unresolved Questions
Critical knowledge gaps remain that will shape research directions:
What triggers the initial misfolding of α-syn? The upstream events initiating aggregation in sporadic PD are unknown. Genetic factors, environmental exposures, and aging-related changes may all contribute.
What determines which neurons are first affected? The selective vulnerability of specific neuronal populations (e.g., substantia nigra dopaminergic neurons) remains incompletely understood but likely involves a combination of intrinsic properties and network position.
How do different strains influence disease phenotype? The relationship between α-syn strain characteristics and clinical presentation requires further investigation. Strain-specific therapies may be necessary.
Can we detect and block the earliest steps in propagation? Biomarkers detecting the initial aggregation events could enable intervention before widespread pathology.
What is the relative contribution of spreading versus independent vulnerability? The prion-like spreading model may not fully explain PD pathogenesis—neuronal vulnerability independent of propagation likely also plays a role.Emerging Research Areas
Several promising directions are likely to advance the field:
- Single-molecule imaging of α-syn aggregation in living neurons using advanced microscopy techniques
- In vitro modeling using stem cell-derived neurons from PD patients to study propagation mechanisms
- Cryo-EM structural studies of patient-derived α-syn fibrils to define strain structures at atomic resolution
- Real-time imaging of propagation in animal models using fluorescently labeled α-syn
- Systems biology approaches integrating genetic, proteomic, and imaging data to model disease progression
Recent Advances (2021-2026)
Strain Diversity and Disease Phenotype
Research since 2020 has revealed that α-syn strains exhibit remarkable structural diversity that correlates with clinical phenotype. Different α-synucleinopathies (PD, DLB, MSA) are associated with distinct strain conformations that determine the pattern of pathology and clinical presentation[@peng2021][@beyerle2022].
Key advances:
- Patient-derived fibril structures resolved by cryo-EM reveal strain-specific fold patterns
- Strain typing via seed amplification followed by PMCA or RT-QuIC can distinguish PD from MSA with high sensitivity
- Cognitive decline correlation: specific strains correlate with faster cognitive progression in PD[@chen2024]
- Cross-seeding: Strains can cross-seed with Aβ and tau, explaining co-pathology in some patients
Human Neuron Models of Propagation
Human iPSC-derived neurons and assembloid models have provided unprecedented insight into α-syn propagation mechanisms:
- Neuron-to-neuron transfer demonstrated in human neuronal cultures with real-time imaging[@kim2023]
- Assembloid models combining brain organoids with motor neurons replicate Braak-like staging progression[@yang2025]
- Strain-dependent synaptic dysfunction observed at pre-aggregational stages in human neurons
A newly characterized pathway for α-syn release involves ectosomes—large extracellular vesicles distinct from exosomes[@zhang2025]:
- Ectosomes (100 nm-1 μm diameter) carry α-syn oligomers and fibrils
- This pathway is distinct from exosomal release and is enhanced by cellular stress
- Ectosome-mediated transfer is more efficient at delivering α-syn to recipient cells
LRRK2 and α-Syn Convergence
Recent work has clarified how LRRK2 mutations influence α-syn propagation[@sekiya2025]:
- LRRK2 phosphorylates Rab8a and Rab10, which regulate exosome trafficking and secretion
- G2019S LRRK2 mutation enhances exosomal release of α-syn oligomers
- Combined LRRK2 G2019S and GBA mutations create synergistic acceleration of propagation
Therapeutic Implications
The 2021-2026 advances have reshaped therapeutic strategies:
Strain-specific targeting: Different strains may require different therapeutic approaches
Early intervention: Human neuron data suggest propagation begins early, supporting early treatment
Combination therapy: Targeting both aggregation and propagation may be synergistic[@chen2025]
Biomarker development: RT-QuIC and PMCA validated for early detection in prodromal PDConclusions
The prion-like spreading mechanism provides a unifying framework for understanding PD progression from early non-motor symptoms to widespread neurodegeneration. The identification of cell-to-cell transmission pathways, templating mechanisms, and strain diversity has opened unprecedented therapeutic opportunities. Current clinical trials targeting aggregation, transmission, and clearance represent the translation of this hypothesis into disease-modifying interventions. Future research will need to determine the relative contributions of spreading versus independent vulnerability, develop sensitive biomarkers for early detection, and optimize combinatorial therapies targeting multiple steps in the propagation cascade. The identification of cell-to-cell transmission pathways, templating mechanisms, and strain diversity has opened unprecedented therapeutic opportunities. Current clinical trials targeting aggregation, transmission, and clearance represent the translation of this hypothesis into disease-modifying interventions. Future research will need to determine the relative contributions of spreading versus independent vulnerability, develop sensitive biomarkers for early detection, and optimize combinatorial therapies targeting multiple steps in the propagation cascade.
See Also
- [Tau Propagation Mechanisms](/mechanisms/tau-propagation-mechanisms)
- [Lewy Body Pathology](/mechanisms/lewy-body-formation)
- [Parkinson's Disease Biomarkers](/mechanisms/parkinsons-disease-biomarkers)
- [Neuroinflammation in Parkinson's](/mechanisms/neuroinflammation-parkinsons)
- [Mitochondrial Dysfunction in Parkinson's](/mechanisms/mitochondrial-dysfunction-parkinsons)
References
[Braak et al., Staging of brain pathology related to sporadic Parkinson's disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12610612/))
[Jucker et al., Propagation of tau and alpha-synuclein in the brain (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21831638/))
[Kalia et al., Alpha-Synuclein and Lewy body pathology (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23919991/))
[Visanji et al., Alpha-synuclein and the pathogenesis of Parkinson's disease (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26555073/))
[Spillantini et al., Alpha-synuclein in Lewy bodies (1997) (1997)](https://pubmed.ncbi.nlm.nih.gov/9196468/))
[Conway et al., Acceleration of oligomerization by Parkinson's disease mutations (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9700192/))
[Fujiwara et al., α-Synuclein is phosphorylated at Ser129 (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11938366/))
[Fujiwara et al., Phosphorylated α-synuclein in Lewy bodies (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11938366/))
[Hasegawa et al., Phosphorylated α-synuclein in Parkinson's disease (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/11835474/))
[Giasson et al., Nitration of α-synuclein in Lewy bodies (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10781079/))
[Liu et al., C-terminal truncation of α-synuclein (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15615635/))
[Peelaerts et al., α-Synuclein strains in Parkinson's disease (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26393878/))
[Boutajangout et al., Lewy body-like pathology in transgenic mice (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21831638/))
[Emmanouilidou et al., Cell-to-cell transmission of α-syn (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20823261/))
[Grey et al., Extracellular α-synuclein in exosomes (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25849662/))
[Wang et al., Tunneling nanotube-mediated transfer of α-syn (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/29175058/))
[Kayed et al., Pore formation by oligomers (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14678879/))
[Sung et al., Exosomal release of mutant α-syn (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15857586/))
[Auluck et al., Mechanisms of cell-to-cell transmission (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20974944/))
[Desplats et al., Inclusion formation after α-syn transmission (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19615870/))
[Guo et al., Cross-seeding between α-syn and Aβ (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24361083/))
[Luk et al., Seed-dependent differences in α-syn pathology (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27530739/))
[Zhang et al., Network model of α-syn propagation (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27221050/))
[Luk et al., Pathological propagation of α-syn in mice (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22236795/))
[Cheng et al., Synaptic α-synuclein pathology in Parkinson's disease (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20153049/))
[Lundblad et al., Pathogenesis of Parkinson's disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22884263/))
[Harrison et al., Neuroinflammation in α-synucleinopathies (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32832622/))
[Cremades et al., Oligomer toxicity mechanisms (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22753587/))
[Rockenstein et al., Differential effects of oligomers vs fibrils (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24954868/))
[Braak et al., Vagal input to the brain (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12927086/))
[Fairfoul et al., Alpha-synuclein RT-QuIC in PD (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26939840/))
[Valera et al., Immunotherapy for α-synucleinopathies (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28488052/))
[Wong et al., Strain differences in α-synucleinopathies (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31144235/))
[Spillantini et al., DLB pathology and clinical features (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/9818054/))
[Forno et al., The neuropathology of Parkinson's disease (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8818769/))
[Duffy et al., Tau and alpha-synuclein propagation in neurodegeneration (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29626758/))
[Ma et al., Alpha-synuclein and mitochondrial dysfunction in PD (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30176611/))
[Schondorf et al., Aggregated α-synuclein initiates mitochondrial damage (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25079146/))
[Di Maio et al., α-Synuclein binds to mitochondria and induces dysfunction (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27221050/))
[Ludtmann et al., α-Synuclein oligomers disrupt mitochondrial integrity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30658742/))